Authors' objectives: To evaluate the effectiveness of PDAs in relation to drug treatment. To identify, in the scientific literature, the prioritization criteria used for the production of these aids. To identify, in the scientific literature, the barriers to the incorporation of PDAs in regular clinical practice. To perform a systematic review of the literature, different search strategies were used in the following electronic databases: MEDLINE (Ovid), EMBASE, CINAHL, Cochrane Library, CRD Databases (DARE, NHS EED and HTA), ECRI and HAYES, up to May 2010 and focused on the objective of the document. The review conducted in 2009 by O’Connor et al, and their data search strategy of July 2006, was used as a starting point. Thesaurus terms, free text and manual searches of articles were used. Randomized clinical trials, systematic reviews and meta-analyses were included. Searches were only limited by date, updating the review by O’Connor et al. (2009). There were no language limits. The quality of the studies included in the review was assessed as part of the critical reading of the studies and results extraction. The various studies were read and a qualitative synthesis made, assessing their methodology using the scales proposed for the classification of scientific evidence by the Critical Appraisal Skills Programme, adapted to Spanish (CASPe), for each type of item, i.e. CASPe was used for clinical trials and systematic reviews. The search identified 337 references, of which 262 were excluded after reading the title and abstract, and 40 were excluded for reasons of duplication. Thirty five articles were selected that were potentially relevant, and 10 articles were finally selected that were used in preparing this report. For the synthesis of the results, specific tables were created where results were pooled by pathologies, detailing the benefits of incorporating PDAs in clinical practice and the barriers to their incorporation. The documents located focused on diabetes, atrial fibrillation, breast cancer, rheumatoid arthritis, schizophrenia and asthma. All the PDAs presented the common feature of being used in conditions that significantly limit the quality of life. The documents located focused on diabetes, atrial fibrillation, breast cancer, rheumatoid arthritis, schizophrenia and asthma. Currently those PDAs are prioritized which focus on drug treatment for: diseases with possible intervention by the patient in the disease management. lengthy treatment of diseases. chronic diseases. oncological diseases. The incorporation of PDAs on drug treatment showed the following results: the acquisition or improvement of skills and knowledge aboutthe disease and possible treatment options occurred in those patients who used PDAs. there was insufficient scientific evidence found for a positive impact on the satisfaction or the decisional conflict of the patient. no scientific evidence was found on whether the incorporation of PDAs in clinical practice was influenced by the severity of the disease and the vital risk to patients, although this aspect was not sufficiently investigated in the studies found. • The information provided by the PDAs should be supported by the best available scientific evidence. Data should be presented clearly, tailored to the patient and the risks-benefits of various treatment options quantified. In addition, the professionals should incorporate the values and preferences of the patient into decision making. Barriers to the incorporation of PDAs in clinical practice were identified that were related to professionals, patients and the distribution channels for their dissemination.

Project Status: Completed

URL for project: https://www.aetsa.org/publicacion/priorizacion-de-herramientas-de-ayuda-a-la-toma-de-decisiones-para-pacientes-hatd-p/

Year Published: 2011

URL for published report: https://www.aetsa.org/download/publicaciones/antiguas/AETSA_2009-4_priorHATD.pdf

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: Spain

Organisation Name: Andalusian Health Technology Assessment Area

Contact Address: Area de Evaluacion de Tecnologias Sanitarias Sanitarias de Andalucia (AETSA) Avda. Innovación, s/n Edificio Arena 1. Sevilla (Spain) Tel. +34 955 006 309

Contact Name: aetsa.csalud@juntadeandalucia.es

Contact Email: aetsa.csalud@juntadeandalucia.es

Copyright: Andalusian Agency for Health Technology Assessment (AETSA)